All‐cause mortality · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in mortality compared with no prophylaxis (moderate certainty).
1 finding from 1 review
All‐cause mortality · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis showed no clear difference in mortality compared with no prophylaxis (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients with cancer with venous thromboembolism
Fondaparinux showed no clear difference in mortality compared with heparin (low certainty).
1 finding from 1 review
All‐cause mortality · patients with the initial treatment of venous thromboembolism in patients with cancer
Dalteparin showed no clear difference in mortality compared with tinzaparin (low certainty).
1 finding from 1 review
All‐cause mortality · patients with cancer with venous thromboembolism
Low molecular weight heparin showed no clear difference in mortality compared with unfractionated heparin (low certainty).
1 finding from 1 review
All‐cause mortality · Adult patients with cancer who develop a low‐risk febrile neutropaenic event
Outpatients showed no clear difference in mortality compared with inpatients ‐ adults (moderate certainty).
1 finding from 1 review
All‐cause mortality · Children with cancer who develop a low‐risk febrile neutropaenic event
Outpatients showed no clear difference in mortality compared with inpatients ‐ children (moderate certainty).
1 finding from 1 review
All‐cause mortality · people living beyond cancer
Dietary intervention showed no clear difference in mortality compared with control (low certainty).
1 finding from 1 review
All‐cause mortality · febrile neutropenia
Early discontinuation of antibiotic treatment showed no clear difference in mortality compared with treatment until neutropenia resolution (low certainty).
1 finding from 1 review
All‐cause mortality · People undergoing radiation therapy for head and neck cancer
Hyperbaric oxygen leads to lower mortality compared with air breathing to enhance the effectiveness of radiotherapy (high certainty).
1 finding from 1 review
All‐cause mortality · People undergoing radiotherapy for uterine cervical cancer
Hyperbaric oxygen showed no clear difference in mortality compared with air breathing (high certainty).
1 finding from 1 review
All‐cause mortality · participants with cancer treated with chemotherapy
1 finding from 1 review
All‐cause mortality · participants with cancer treated with radiotherapy (with or without chemotherapy)
1 finding from 1 review
All‐cause mortality · participants with cancer treated with radiotherapy (with or without chemotherapy)
2 findings from 1 review
All‐cause mortality · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in mortality compared with UFH prophylaxis (moderate certainty).
1 finding from 1 review
All‐cause mortality · Adults undergoing pelvic radiotherapy
1 finding from 1 review
no estimate extracted
905 participants
Very low
All‐cause mortality
Heparin prophylaxis showed no clear difference in mortality compared with no prophylaxis (moderate certainty).
2 findings from 1 review
All‐cause mortality · people with cancer who have febrile neutropenia
Oral showed no clear difference in mortality compared with intravenous antibiotic therapy (moderate certainty).
1 finding from 1 review
Mortality ( · adults with chordoma
It is very uncertain whether protons changes mortality ( compared with photons (very low certainty).
1 finding from 1 review
HR 0.44 [0.13, 1.57]
65 participants
Very low
HGSC mortality
2 findings from 1 review